Evidence map›Paper›PMID 41900838›Full record

ArticlePharmaceutics2026

Sodium Alendronate-Modified PLGA-mPEG Nanomicelles Loaded with Rifapentine for Targeted Delivery to Bone Tissue.

Weilin Wang, Xin Cui, Hengfa Wei, Jingjing Wang, Yesbolat Ahehati, Cuiping Jiang, Fei Li, Shasha Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Weilin WangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Xin CuiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Hengfa WeiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Jingjing WangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Yesbolat AhehatiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Cuiping JiangGuangdong Provincial Key Laboratory of Chinese Medicine Pharmaceutics, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
Fei LiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.
Shasha LiState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, College of Pharmacy, Xinjiang Medical University, Urumqi 830054, China.

Funding

Natural Science Foundation of Xinjiang Uygur Autonomous Region 2024D01C127State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia SKL-HIDCA-2023-YX4
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

bisphosphonatesbone targetingdrug delivery systempolymeric micellesrifapentine

Identifiers

PMID41900838
PMCPMC13029411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.